Showing results (61-70 of 130) with videos related to
Sort By:
Pageof 13
Cardiovascular Diabetology|June 7, 2019
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trialLawrence A Leiter, Stephen C Bain, Irene Hramiak, et al.Diabetes, Obesity & Metabolism|February 11, 2026
Comparison of pharmacodynamics and pharmacokinetics of ultra-rapid-acting insulin aspart and rapid-acting insulin aspart around continuous moderate intensity exercise in adults with type 1 diabetes: A randomised controlled trialJason P Pitt, Alexander Müller, Chloe Nicholas, et al.Diabetology & Metabolic Syndrome|December 5, 2017
Poor glycaemic control is associated with reduced exercise performance and oxygen economy during cardio-pulmonary exercise testing in people with type 1 diabetesOthmar Moser, Max L Eckstein, Olivia McCarthy, et al.Diabetes Care|May 16, 2012
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targetsJ Hans DeVries, Stephen C Bain, Helena W Rodbard, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 1, 2024
Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational StudySharmistha Roy Chowdhury, Fethi Sadouki, Edward Collins, et al.Diabetes, Obesity & Metabolism|November 28, 2017
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathyTina Vilsbøll, Stephen C Bain, Lawrence A Leiter, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 14, 2019
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial ProgrammeStephen C Bain, Brian B Hansen, Samuel J P Malkin, et al.Diabetes & Metabolic Syndrome|July 15, 2018
Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinicDavid M Williams, Natasha Shrikrishnapalasuriyar, Waheeba Syed, et al.Kidney International|February 4, 2023
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placeboKatherine R Tuttle, Heidrun Bosch-Traberg, David Z I Cherney, et al.Journal of Diabetes and Its Complications|June 11, 2013
One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c targetJulio Rosenstock, Helena W Rodbard, Stephen C Bain, et al.Pageof 13